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1. Introduction 
Bladder cancer occurs with a relatively high incidence in industrial nations. For example, 
bladder cancer is the fourth most common type of cancer in American men. The estimated 
U.S. incidence in 2008 was 68,810 cases and the mortality was 14,100 cases (Jemal et al., 
2008). Of newly diagnosed bladder cancer cases, approximately 70% - 80% will present with 
non muscle-invasive disease. Among such cases, 50% - 70% will recur, and 10% - 30% will 
progress to muscle-invasive disease (Soloway et al., 2002; Saad et al., 2002). Radical 
cystectomy with or without chemotherapy is the standard therapy for muscle-invasive 
disease; however, some patients will experience metastatic relapse after radical surgery. A 
few patients present with metastatic disease upon their initial presentation at the hospital. 
Such advanced bladder cancer remains an incurable terminal disease, and accounts for 3% 
of the cancer-related mortality in the United States. Deaths from bladder cancer are mainly 
related to distant spread; hence, prevention of metastatic disease remains a crucial goal in 
this disease. Systemic chemotherapy achieves palliation, survival benefit, and occasional 
long-term remissions. For the last two decades, cisplatin-based combination therapies have 
evolved as the standard. The MVAC regimen (Sternberg et al., 1988) was reported to 
demonstrate an impressive complete remission rate of 37% in advanced urothelial 
carcinoma (UC), and in a subsequent comparative study was found to be superior to the 
single agent cisplatin (Saxman et al., 1997). In this chapter, we review the recent progress in 
chemotherapeutic regimens not only for advanced bladder cancer, but also for advanced UC 
in the upper urinary tract. We also show current data on the efficacy of combination therapy 
with gemcitabine and platinum anti-cancer drugs, which is mainly used as a second-line 
treatment in our institution.  
2. The first successful chemotherapeutic regimen for advanced Urothelial 
Carcinoma (UC) 
Despite recent developments in anti-cancer drugs, advanced UC remains an incurable disease, 
with a median survival time of only 12 to 14 months (Jemal et al., 2003). The most reliable 
treatment option for advanced UC is considered to be combination chemotherapy including a 
platinum anti-cancer drug. The combination chemotherapy regimen of methotrexate / 
vinblastine / doxorubicin / cisplatin (MVAC) as reported originally by Sternberg (Sternberg et 
al., 1988) is currently being used worldwide with superior efficacy. However, MVAC 
treatment is associated with substantial toxicities and has a toxic death rate of approximately  
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3 - 4% (Sternberg et al., 1989; Loehrer et al., 1992). Therefore, the need for an alternative less 
toxic combination chemotherapy that can provide efficacy similar or superior to the MVAC 
regimen has been identified. Gemcitabine, a nucleoside analogue, has demonstrated activity 
against a range of solid tumors, including metastatic UC (Gatzemeier et al., Moore, 1996; 
Stadler et al., 1997). In particular, gemcitabine alone has yielded a response rate of 23 - 29%, 
with a complete response rate of 4 - 13%, in both previously treated and untreated metastatic 
UC patients (Sternberg, 2000). The good activity and toxicity profiles of single-agent 
gemcitabine treatment and its synergism with cisplatin in pre-clinical models (Peters et al., 
1995) led to the development of this combination for the treatment of advanced UC. After 
obtaining results from phase 2 trials of combination therapy comprising gemcitabine plus 
cisplatin (GC) as first- or second-line treatment for UC, von der Maase et al. published a large 
multinational phase 3 trial comparing MVAC with GC therapy, with a total of 405 patients 
accrued (von der Maase et al., 2000). The final results show that the two regimens are similar in 
terms of response rate, time to progression and survival. However, the GC combination 
showed a better safety profile and tolerability than MVAC. The representative randomized 
trials on MVAC and GC are summarized in Table 1. Carboplatin shares a common mechanism 
of action with cisplatin, but the two have different pharmacokinetic and dose-limiting 
toxicities (Van Echo et al., 1989). Patients with UC are often elderly, and frequently have 
clinical or subclinical renal function impairment. Thus, the substitution of carboplatin for 
cisplatin offers a promising alternative for these patients. There have been several phase 2 
reports showing that gemcitabine / carboplatin achieved clinical results equivalent to those of 
GC (Xu et al., 2007; Dogliotti et al., 2007). It can thus be speculated that the combination of 
gemcitabine plus a platinum anti-cancer drug (cisplatin or carboplatin) is currently being used 
worldwide in the treatment of advanced UC. 
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3. The efficacy and safety of combination chemotherapy with gemcitabine 
and a platinum anti-cancer drug. A regimen mainly used as second-line 
chemotherapy for patients with advanced UC at Tottori university hospital 
Our original data regarding the effects of combination therapy with gemcitabine plus 
platinum anti-cancer drug as second-line chemotherapy for cases of advanced UC are 
described below. These data were gathered mainly as a result of limitations in the Japanese 
insurance system, which until recently did not cover the use of gemcitabine for the 
treatment of UC. That is, before February 2009, the use of gemcitabine was not allowed for 
general use in Japan, and thus only referral academic institutions such as ours were able to 
conduct gemcitabine therapy. Because the incurable rate is still high in advanced UC 
patients to date in spite of the medical progress of many anti-cancer drugs in Japan and 
other countries, physicians often encounter patients with advanced UC who need to 
undergo more than one kind of chemotherapy. Therefore sequential data of second-line 
chemotherapy like ours is considered to be useful for urological oncologists worldwide. In 
this paragraph, the therapeutic data for cases of upper urinary tract UC are also included. 
This book is of course about bladder cancer; however, it is often difficult to isolate the 
therapeutic data for bladder cancer from the data for all cases of UC. Therefore, we regret 
that we cannot describe the results for bladder cancer data specifically.  
3.1 Patients’ characteristics 
From December 2004 until September 2011, 30 patients received the combination 
chemotherapy of gemcitabine plus a platinum anti-cancer drug (cisplatin or carboplatin) at 
 
 
Table 2. Patient characteristics 
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our institution. All patients were evaluated for efficacy and for toxicity. The pretreatment 
characteristics of the patients are listed in Table 2. 23 patients (77%) had previously received 
combination chemotherapy of methotrexate / epirubicin / cisplatin (MEC). 
3.2 Treatment plan 
In the first cycle of the therapy, the creatinine clearance (Ccr) (ml / min) of each patient was 
measured prior to initiation of the therapy. In the patients with Ccr > 60, cisplatin was 
administered, while in those with Ccr ＜ 60, carboplatin was administered as the platinum 
anti-cancer drug. Gemcitabine (1,000 mg / m2) was given by intravenous infusion over 30 – 
60 min on days 1, 8, and 15. Cisplatin (70 mg / m2) was given by intravenous infusion over 
30 – 60 min on day 2 in the cisplatin group, whereas carboplatin dosed to an AUC of 5 was 
given by intravenous infusion over 30 – 60 minutes on day 2 in the carboplatin group. 
Basically, each cycle consisted of 21 days. However, an extension of the days in each cycle 
was permitted based on the judgment of the physician in charge if any severe adverse 
events were noted. All toxicities were recorded according to the National Cancer Institute 
Common Toxicity Criteria (NCI-CTC) version 3.0. Dose adjustment during the treatment 
was based on hematological and non-hematological assessment of toxicities. In the 
hematological assessment of toxicities, leukocyte and platelet counts were generally 
measured weekly. For cases where leukocytes < 2,000 / mm3 or platelets < 75,000 / mm3, or 
where there was evidence of bleeding, gemcitabine was omitted. No new cycle was started 
unless leukocytes were > 2,000 / mm3 and platelets were > 75,000 / mm3. The platinum anti-
cancer drug dose was reduced by 50% for grade 2 neurotoxicity, omitted for grade 3, and 
stopped for grade 4. For renal toxicity, the dose of platinum anti-cancer drug was reduced 
by 50% for Ccr 50 – 59, and omitted for Ccr ＜ 50. For other grade 3 non-hematological 
toxicities (except nausea, vomiting, and alopecia), gemcitabine and platinum anti-cancer 
drug doses were reduced by 50% or omitted per the physician in charge. For grade 4 
toxicities, doses were reduced by 50% or stopped (unless the patient was responding to the 
therapy).  
3.3 Dose administration 
The median number of consecutive cycles per patient was 3 (range: 1 – 7). 16 patients (53%) 
underwent more than 3 cycles of the therapy. Cisplatin was administered in 12 patients 
(40%), while carboplatin was administered in 18 patients (60%) as the platinum anti-cancer 
drug (Table 3). 
3.4 Efficacy 
All 30 patients were assessed with regard to clinical outcome and treatment efficacy 
according to RECIST criteria at the end of the study. With regard to clinical outcome (Table 
3), we observed 2 (7%) cases of complete response (CR) and 7 (23%) cases of partial response 
(PR), with an overall response rate (ORR) of 30%. The visceral field of metastasis or relapse 
in patients of CR and PR was the lungs in 3 cases, lymph nodes in 5 cases, and local relapse 
(post-nephroureterectomy) in 1 case. There were no cases with responses in other visceral 
fields such as bone. Stable disease (SD) was identified in 10 patients (33%), and progressive 
disease (PD) in 9 patients (30%). 2 patients (7%) were not evaluated. The median time to 
follow-up was 11.7 months (range: 0.8 – 65.8 months). The median overall survival (OS) was 
11.1 months. Kaplan-Meier curves for OS are shown in Fig. 1. 
www.intechopen.com
 




Table 3. Treatment profile and efficacy 
 
 
Fig. 1. Overall survival rate of all 30 patients with advance UC treated at Tottori University 
Hospital 
3.5 Toxicity 
Only 1 patient discontinued the therapy simply for reasons of toxicity; this patient showed a 
Grade 2 allergic reaction to gemcitabine, which was administered on day 15. Since this 
patient eventually received one whole cycle of the therapy, we assessed the efficacy of the 
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treatment as such. Grade 3 / 4 neutropenia was the most frequent toxicity, occurring in 63% 
of the patients. Grade 3 / 4 thrombocytopenia was also a frequent toxicity, occurring in 57% 
of the patients. Grade 3 / 4 non-hematologic toxicities included nausea and vomiting in 1 
patient (3%). Major toxicities according to NCI-CTC are summarized in Table 4. No other 
types of major toxicities such as nephrotoxicity or neurotoxicity were observed in any 
patients. In order to analyze the cumulative damage due to hematologic side effects, the 
nadir values of blood counts were analyzed. The nadir values of hemoglobin and the nadir 
counts of leukocytes and platelet cells in the first cycle were practically the same as those in 
the other progressive cycles. In other words, hematological toxicities were not enhanced by 
the progressive repetition of cycles (data not shown). 
 
 
Table 4. Mayor toxicities according to NCI-CTC 
3.6 Conclusions 
The efficacy of gemcitabine plus a platinum anti-cancer drug as a second-line chemotherapy 
for advanced UC was found to be modest. The toxicity of the therapy was tolerable despite 
damage from previous chemotherapy and repeated cycles. The present data, obtained as a 
result of particular limitations in the medical insurance industry in Japan, will be helpful 
when considering the best course of second-line chemotherapy for cases of advanced UC in 
the future. 
4. Is there any effective combination chemotherapy except MVAC or GC for 
advanced UC? 
― The combination therapy of methotrexate / epirubicin / cisplatin (MEC) ― 
The combination chemotherapy of methotrexate, epirubicin and cisplatin (MEC) was mainly 
developed in Japan for the purpose of establishing a regimen less toxic than MVAC but with 
equal efficacy. Several academic Japanese institutions including the Japanese Urothelial Cancer 
Research Group promoted a randomized trial comparing MEC and MVAC (Kuroda et al., 
1998). Total of 89 patients were assigned to three groups receiving either standard MEC (S-
MEC), dose-intensified MEC (I-MEC) or MVAC. The S-MEC regimen consisted of 
methotrexate (30 mg / m2), epirubicin (50 mg / m2) and cisplatin (100 mg / m2), and that of 
the I-MEC regimen was methotrexate (36 mg / m2), epirubicin (60 mg / m2) and cisplatin (120 
mg / m2). In both groups, methotrexate was administered on day 1 and 15, epirubicin was 
administered on day 1, and cisplatin was administered on day 2. In the I-MEC group, G-CSF 
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(2μg / kg) was administered from day 3 until day 12 routinely. The response rates (CR + PR) 
were 52% with S-MEC, 76% with I-MEC and 47% with MVAC. All of the adverse events were 
rendered tolerable in the S-MEC and I-MEC groups through the use of G-CSF agents. We had 
been utilizing MEC as a first choice therapy until 2008 in our institution because it was less 
toxic than but as effective as MVAC. As a matter of fact, most of the patients in our study of 
second-line combination chemotherapy with gemcitabine and the platinum anti-cancer drugs 
described above had been receiving MEC as the first line chemotherapy at other institutions. 
5. Prevention of micro metastasis and effort of tumor reduction by 
neoadjuvant chemotherapy at radical cystectomy 
In T2-4 (invasive) bladder cancer, neoadjuvant chemotherapy with MVAC or cisplatin, 
methotrexate, and vinblastine has demonstrated significant progression-free survival (PFS) 
and OS benefit in several randomized trials. One representative trial is the Intergroup 8710 
trials reported by Grossman et al. in which cystectomy alone was compared with 
neoadjuvant MVAC followed by radical cystectomy. The group receiving neoadjuvant 
chemotherapy had an increased likelihood of eliminating residual cancer in the cystectomy 
specimen (pT0) and had an associated improved survival. Moreover, neoadjuvant 
chemotherapy did not adversely affect the patient’s chance of undergoing a cystectomy and 
did not increase the risk of postoperative complications (Grossman et al., 2003). In the 
combined analysis of 2 Nordic studies, neoadjuvant platinum-based combination 
chemotherapy was associated with an 8% increase in survival at 5 years (Sherif et al., 2004). 
A meta-analysis of randomized controlled trials demonstrated a survival benefit to receiving 
neoadjuvant chemotherapy (Winquist et al., 2004). Carboplatin-based regimens have been 
evaluated in the neoadjuvant setting only in phase 2 trials, and hence their use in the 
neoadjuvant or adjuvant setting cannot be recommended (Smith et al., 2008; deVele White et 
al., 2009). The studies of adjuvant chemotherapy have demonstrated conflicting results. 
They have had design flaws and small sample sizes and are therefore underpowered to give 
a conclusive answer regarding the benefits. 
6. Other recent chemotherapeutic regimens including taxanes 
The taxanes are diterpenes produced by the plants of the genus Taxus (yews), and include 
such compounds as docetaxel and paclitaxel, the latter of which was originally derived from 
the Pacific yew tree. The principal mechanism of action of the taxane class of drugs is the 
disruption of microtubule function. Microtubules are essential to cell division, and taxanes 
stabilize GDP-bound tubulin in the microtubule, thereby inhibiting the process of cell 
division. Thus, in essence, taxanes are mitotic inhibitors. Both paclitaxel and docetaxel have 
been studied as chemotherapeutic agents for metastatic bladder cancer. Paclitaxel-based 
regimens in combination with either cisplatin or carboplatin have been evaluated with 
response rates between 16% and 36% and median survival ranging from 6 to 10 months 
depending on the characteristics of the patients enrolled and whether they are ciplatin-
sensitive or a refractory population (Vaishampayan et al., 2005; Uhm et al., 2007). A phase 3 
study comparing docetaxel and cisplatin (DC) with G-CSF versus MVAC with G-CSF found 
MVAC to be more effective than DC for metastatic cancer; MVAC demonstrated both a 
superior median time to progression (9.4 vs 6.1 months; P = 0.003) and median survival time 
(14.2 vs 9.3 months; P = 0.026) (Bamias et al., 2004). Other recent representative reports of 
taxanes with cisplatin therapy are shown in Table 5. Antifolates such as trimetrexate and 
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premetrexed have been better tolerated with promising response rates and should be 
promising for future evaluation (Witte et al. 1994; Sweeney et al., 2006). Oxaliplatin-based 
regimens have been evaluated and also shown to be of modest benefit (Carles et al., 2007). 
 
 
Table 5. Recent representative reports of taxanes with cisplatin therapy for advanced 
urotherial cancer 
7. Role of targeted therapies in bladder cancer 
The actual clinical advent of targeted therapies has been slower in UC, as compared to other 
solid tumors due to large variations in histology worldwide, as well as the difficulty in 
accruing to clinical trials with this malignancy. Vaishampayan et al. evaluated and reported 
the frequency of overexpression of Her-2 in bladder cancer and correlated with the Her-2 
expression in metastatic sites. Interestingly, the overexpression of her-2 by 
immunohistochemistry (IHC) (2+ or 3+) was 37% in primary bladder tumor tissue, the 
expression in metastatic sites such as lymph nodes was 63% and  the expression in visceral 
metastases was 86% (Vaishampayan, 2009). 45% of Her-2/neu-negative primaries had Her-
2/neu-positive lymph node metastases, while 92% of Her-2-positive primary tumors were 
associated with Her-2-positive metastasis. This finding suggested that Her-2 over-
expression could be a useful therapeutic target for advanced UC. Hence, a phase 2 trial was 
conducted and reported evaluating the role of trastuzumab with chemotherapy in 
metastatic UC. An extremely promising 70% response rate and a favorable median survival 
of 14 months were noted despite 55% of the patients having visceral metastases (Hussain et 
al., 2007). Another novel approach using molecular targeted therapy for advanced UC 
patients is the combination therapy of bevacizumab and chemotherapeutic agents. A phase 
2 study of bevacizumab in combination with cisplatin and gemcitabine in metastatic or 
locally advanced bladder cancer involving 36 patients showed a complete response in 6 
(17%), and a partial response in 18 (50%); this combination is now being studied in a phase 3 
trial (Dovedi & Davies, 2009; Hahn et al., 2011). Another study with anti-angiogenic therapy 
is the evaluation of sunitinib in a placebo-controlled double-blind trial with the goal of 
sustaining or prolonging response, after initial chemo-therapy in advanced bladder cancer 
(Bradley et al., 2007). Epithelial growth factor receptor has also been identified as an exciting 
target in UC. The over-expression of EGFR by IHC is noted in about 92% (35 of 38) of the 
bladder cancer cases at Wayne State University; however, its association with survival 
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outcome has not been established (Bellmunt et al., 2003). Given the possibility of EGFR-
targeted therapy, a phase 2 randomized trials of cisplatin and gemcitabine with or without 
cetuximab (a monoclonal antibody to EGFR) is ongoing as a frontline therapy for metastatic 
UC. Current and future additional trials of targeted therapy are listed in Table 6. 
 
 
Table 6. Current and future trial with targeted therapy 
8. Conclusions 
Since the breakthrough progress of development MVAC chemotherapy by Sternberg for 
advanced UC patients, the survival of such patients has been prolonged compared with 
those of untreated patients. However, despite the development of anti-cancer drugs, 
metastatic bladder cancer is still not considered a curable disease. Numerous efforts to 
achieve improved curability are going, including investigations into molecular targeted 
therapy, which has just been developed as a breakthrough treatment for patients with 
advanced renal cell carcinoma in the same field of urologic oncology.  
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